Kairos Pharma, Ltd., specializing in developing new cancer treatments, has started a Phase 1 trial of its leading combination therapy. The study tests their drug ENV105 with osimertinib against non-small cell lung cancer.

Adagene Inc., a leader in antibody therapeutics, shared research at the 2024 ASCO Symposium on Gastrointestinal Cancers in San Francisco.

Regenxbio announces phase II aaviate ® The interim data of the trial were positive. Abbv-rgx-314 administered through sclera was used to treat wet AMD.

Initial findings from a Phase 1b trial examining treatments with Quemliclustat suggest encouraging survival rates for patients with previously untreated advanced pancreatic cancer.

Vertex Discloses Clearance by the US FDA for CASGEVY™ (exagamglogene autotemcel) as a Therapeutic Option for Beta Thalassemia Patients Requiring Regular Blood Transfusions.

GALDERMA 2024: Phase III trials of RelabotulinumtoxinA show favorable outcomes and extended effectiveness in addressing both glabellar lines and lateral canthal lines at once.

Aviceda Therapeutics Reveals Preliminary Results from Initial Segment of Phase 2/3 SIGLEC Study on AVD-104, Indicating Encouraging Safety Profile and Initial Efficacy Signals in Individuals with Geographic Atrophy.

Aruna Bio has received FDA approval for its investigational new drug (IND) application, allowing AB126, its pioneering exosome therapy.

Sarepta Therapeutics Launches Participant Selection for Phase 3 Trial, EMERGENE, Investigating SRP-9003 in Limb-Girdle Muscular Dystrophy 2E/R4 Treatment.

CARsgen's candidate, CT011, has secured authorization from the NMPA to proceed with trials for GPC3-positive Ⅲa hepatocellular carcinoma patients with a significant risk of recurrence post-surgery.

Halozyme Reports Roche Granted EU Clearance for Subcutaneous Form of Tecentriq® with ENHANZE® Technology, Marking a Breakthrough in the Delivery of Immunotherapies Across Various Cancers.

Chipscreen NewWay Initiates Phase 1 Study: Administers Initial Dose of Innovative Dual-Targeting Antibody NWY001 for Advancing Cancer Immune Therapy in Individuals with Progressive Solid Cancers.